Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Q2 2025 value amounting to $113000.0.

  • Corvus Pharmaceuticals' Capital Expenditures changed N/A to $113000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $149000.0, marking a year-over-year change of. This contributed to the annual value of $34000.0 for FY2023, which is 8736.06% down from last year.
  • As of Q2 2025, Corvus Pharmaceuticals' Capital Expenditures stood at $113000.0.
  • In the past 5 years, Corvus Pharmaceuticals' Capital Expenditures registered a high of $265000.0 during Q3 2022, and its lowest value of $34000.0 during Q1 2023.
  • For the 3-year period, Corvus Pharmaceuticals' Capital Expenditures averaged around $112000.0, with its median value being $74500.0 (2025).